Columbia Laboratories has a rich heritage in pharmaceutical research and development, particularly in women's healthcare and drug delivery. Our products have used the principles of bioadhesion to achieve controlled, sustained drug delivery. We have developed and brought to market six products, each commercialized through strategic alliances. Our largest single revenue source remains CRINONE® (progesterone gel), which is sold by Actavis in the U.S. and by Merck Serono in over 60 other countries worldwide.
In September 2013, we acquired Molecular Profiles™, a U.K.-based provider of pharmaceutical development and analytical services. Through Molecular Profiles, we offer broad formulation, development, manufacturing and analytical capabilities to clients including large multi-national pharmaceutical companies, specialized drug-delivery firms and biotechs.
CRINONE® is a registered trademark of Actavis, Inc. in the U.S. and of Merck Serono S.A. outside the U.S.
Molecular Profiles™ is a trademark of Molecular Profiles Ltd., a wholly-owned subsidiary of Columbia Laboratories, Inc.